Cargando…

Interactions of IgG1 CH2 and CH3 Domains with FcRn

Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Tianlei, Ju, Tina W., Wang, Yanping, Prabakaran, Ponraj, Dimitrov, Dimiter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980117/
https://www.ncbi.nlm.nih.gov/pubmed/24765095
http://dx.doi.org/10.3389/fimmu.2014.00146
_version_ 1782310815993430016
author Ying, Tianlei
Ju, Tina W.
Wang, Yanping
Prabakaran, Ponraj
Dimitrov, Dimiter S.
author_facet Ying, Tianlei
Ju, Tina W.
Wang, Yanping
Prabakaran, Ponraj
Dimitrov, Dimiter S.
author_sort Ying, Tianlei
collection PubMed
description Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome this problem is through the development of novel antibody fragments based on IgG Fc region, which contributes to the long half-life of IgG through its unique pH-dependent association with the neonatal Fc receptor (FcRn). The IgG Fc region comprises two CH2 and two CH3 domains. In this report, we present a comparative study of the FcRn binding capability of the CH2 and CH3 domains. The stability and aggregation resistance of these domains were also investigated and compared. We found that monomeric CH2 and CH3 domains exhibited the pH-dependent FcRn binding while the dimeric forms of CH2 and CH3 domains did not. Although all of these domains had high serum stability, they had aggregation tendencies as measured by dynamic light scattering. By providing a better understanding of the structure–activity relationship of the Fc fragment, these results guide further approaches to generate novel Fc-based small-size antibody fragments that possess pH-dependent FcRn binding capability, desired in vivo half-lives, and other favorable biophysical properties for their druggability.
format Online
Article
Text
id pubmed-3980117
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-39801172014-04-24 Interactions of IgG1 CH2 and CH3 Domains with FcRn Ying, Tianlei Ju, Tina W. Wang, Yanping Prabakaran, Ponraj Dimitrov, Dimiter S. Front Immunol Immunology Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome this problem is through the development of novel antibody fragments based on IgG Fc region, which contributes to the long half-life of IgG through its unique pH-dependent association with the neonatal Fc receptor (FcRn). The IgG Fc region comprises two CH2 and two CH3 domains. In this report, we present a comparative study of the FcRn binding capability of the CH2 and CH3 domains. The stability and aggregation resistance of these domains were also investigated and compared. We found that monomeric CH2 and CH3 domains exhibited the pH-dependent FcRn binding while the dimeric forms of CH2 and CH3 domains did not. Although all of these domains had high serum stability, they had aggregation tendencies as measured by dynamic light scattering. By providing a better understanding of the structure–activity relationship of the Fc fragment, these results guide further approaches to generate novel Fc-based small-size antibody fragments that possess pH-dependent FcRn binding capability, desired in vivo half-lives, and other favorable biophysical properties for their druggability. Frontiers Media S.A. 2014-04-02 /pmc/articles/PMC3980117/ /pubmed/24765095 http://dx.doi.org/10.3389/fimmu.2014.00146 Text en Copyright © 2014 Ying, Ju, Wang, Prabakaran and Dimitrov. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ying, Tianlei
Ju, Tina W.
Wang, Yanping
Prabakaran, Ponraj
Dimitrov, Dimiter S.
Interactions of IgG1 CH2 and CH3 Domains with FcRn
title Interactions of IgG1 CH2 and CH3 Domains with FcRn
title_full Interactions of IgG1 CH2 and CH3 Domains with FcRn
title_fullStr Interactions of IgG1 CH2 and CH3 Domains with FcRn
title_full_unstemmed Interactions of IgG1 CH2 and CH3 Domains with FcRn
title_short Interactions of IgG1 CH2 and CH3 Domains with FcRn
title_sort interactions of igg1 ch2 and ch3 domains with fcrn
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980117/
https://www.ncbi.nlm.nih.gov/pubmed/24765095
http://dx.doi.org/10.3389/fimmu.2014.00146
work_keys_str_mv AT yingtianlei interactionsofigg1ch2andch3domainswithfcrn
AT jutinaw interactionsofigg1ch2andch3domainswithfcrn
AT wangyanping interactionsofigg1ch2andch3domainswithfcrn
AT prabakaranponraj interactionsofigg1ch2andch3domainswithfcrn
AT dimitrovdimiters interactionsofigg1ch2andch3domainswithfcrn